Holstein A, Hammer C, Plaschke A, Ptak M, Kuhn J, Diekmann J, Kleesiek K, Egberts E-H
1st Department of Medicine, Klinikum Lippe-Detmold, Detmold, Germany.
Exp Clin Endocrinol Diabetes. 2004 Sep;112(8):429-34. doi: 10.1055/s-2004-821188.
To determine the counterregulatory hormonal responses to severe hypoglycaemia (SH) in type 1 versus insulin-treated type 2 diabetic patients under everyday conditions.
Counterregulatory hormones were determined in 28 consecutive type 1 and thirteen insulin-treated type 2 diabetic patients (age 54 +/- 18 vs. 75 +/- 13 yrs; diabetes duration 27 +/- 16 vs. 21 +/- 6 yrs) with SH requiring emergency treatment. Blood samples were taken prior to and after effective treatment of SH. SH was defined as an event with neuroglycopenic presentation requiring external intervention by administration of intravenous glucose or oral carbohydrates. 68 % (19/28) of type 1 diabetic patients but none of those with type 2 diabetes had reduced awareness of hypoglycaemia.
Plasma glucose levels were 30 +/- 14 prior to and 179 +/- 82 mg/dl after treatment of SH; the time between the two measurements was 54 +/- 26 minutes. With the exception of higher levels of human growth hormone in type 1 patients - which were attributed to younger age - the other counterregulatory responses to SH showed no significant differences in type 1 vs. type 2 diabetic patients. In both groups glucagon responses were virtually absent while moderate catecholamine responses could be demonstrated. Treatment with beta-blockers did not affect hormonal counterregulation in type 1 diabetic patients.
In patients approaching the insulin-deficient end of the spectrum of type 2 diabetes the hormonal responses to SH are comparable to those in patients with longstanding type 1 diabetes. Thus, in advanced type 2 diabetes the risk of developing SH may be similar to that in individuals with type 1 diabetes.
确定在日常情况下,1型糖尿病患者与接受胰岛素治疗的2型糖尿病患者对严重低血糖(SH)的对抗调节激素反应。
对28例连续的1型糖尿病患者和13例接受胰岛素治疗的2型糖尿病患者(年龄分别为54±18岁和75±13岁;糖尿病病程分别为27±16年和21±6年)进行了研究,这些患者发生了需要紧急治疗的SH。在SH得到有效治疗之前和之后采集血样。SH被定义为伴有低血糖性神经症状表现、需要通过静脉输注葡萄糖或口服碳水化合物进行外部干预的事件。68%(19/28)的1型糖尿病患者存在低血糖意识减退,而2型糖尿病患者中无一例出现这种情况。
SH治疗前血浆葡萄糖水平为30±14,治疗后为179±82mg/dl;两次测量之间的时间为54±26分钟。除1型患者的人生长激素水平较高(归因于年龄较轻)外,1型与2型糖尿病患者对SH的其他对抗调节反应无显著差异。两组患者的胰高血糖素反应均几乎未出现,而儿茶酚胺反应适度。β受体阻滞剂治疗对1型糖尿病患者激素的对抗调节无影响。
在接近2型糖尿病胰岛素缺乏末期的患者中,对SH的激素反应与长期患1型糖尿病的患者相当。因此,在晚期2型糖尿病中,发生SH的风险可能与1型糖尿病患者相似。